SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

被引:0
作者
M. Dómine
T. Moran
D. Isla
J. L. Martí
I. Sullivan
M. Provencio
M. E. Olmedo
S. Ponce
A. Blasco
M. Cobo
机构
[1] Hospital Universitario Fundación Jiménez Díaz,Medical Oncology Department
[2] IIS-FJD,Medical Oncology Department
[3] Oncohealth Institute,Medical Oncology Department
[4] Catalan Institute of Oncology,Medical Oncology Department
[5] Hospital Universitari Germans Trias i Pujol,Medical Oncology Department
[6] Department of Medicine,Medical Oncology Department
[7] Universitat Autònoma de Barcelona. Badalona-Applied Research Group in Oncology (B-ARGO),Medical Oncology Department
[8] Fundació Institut Germans Trias i Pujol (IGTP),Medical Oncology Department
[9] Hospital Clínico Universitario Lozano Blesa,Medical Oncology Department
[10] Hospital General de Alicante,Medical Oncology Department
[11] Hospital de la Santa Creu i Sant Pau,undefined
[12] Hospital Universitario Puerta de Hierro Majadahonda,undefined
[13] Hospital Universitario Ramón y Cajal,undefined
[14] Hospital Universitario 12 de Octubre,undefined
[15] Consorcio Hospital General Universitario de Valencia,undefined
[16] CIBERONC,undefined
[17] Hospital Regional Universitario de Málaga (Carlos Haya),undefined
来源
Clinical and Translational Oncology | 2020年 / 22卷
关键词
SCLC; Chemotherapy; Immunotherapy; Radiotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15–20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum–etoposide. In stage IIB–IIIC, the recommended treatment is early concurrent chemotherapy with platinum–etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum–etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum–etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.
引用
收藏
页码:245 / 255
页数:10
相关论文
共 99 条
[1]  
Bray F(2018)Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2010)Quality and strength of evidence of the infectious diseases Society of America Clinical Practice Guidelines Clin Infect Dis 51 1147-1156
[3]  
Soerjomataram I(2002)Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer 37 271-276
[4]  
Khan AR(2017)Outcomes of stereotactic body radiotherapy for T1–T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis Clin Lung Cancer. 18 675-681
[5]  
Khan S(2018)Prophylactic cranial irradiation in resected small cell lung cancer: a systematic review with meta-analysis J Cancer 9 433-439
[6]  
Zimmerman V(1999)Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide N Engl J Med 340 265-271
[7]  
Micke P(2017)Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial Lancet Oncol 18 1116-1125
[8]  
Faldum A(2012)Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data J Clin Oncol 30 1692-1698
[9]  
Metz T(2002)Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104 J Clin Oncol 20 3054-3060
[10]  
Verma V(2004)Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer J Clin Oncol 22 4837-4845